Haitian Pharmaceutical

Shanghai Haitian Pharmaceutical Technology Development Co., Ltd. was established in March 2000, registered in the China (Shanghai) Pilot Free Trade Zone with a registered capital of 10 million RMB. It is a wholly-owned subsidiary of Guiyang Xintian Pharmaceutical Co., Ltd. (stock code: 002873), established in Shanghai, and serves as the R&D platform of Xintian Pharmaceutical. Shanghai Haitian Pharmaceutical boasts a dynamic R&D team led by renowned experts and composed mainly of young doctors and masters, with departments including Traditional Chinese Medicine Clinical, TCM Process, Quality Research, New Drug Registration, Drug Information, Project Evaluation I, Project Evaluation II, Project Management, and Project Teams. The company invests over 10 million RMB annually in R&D and has obtained more than 10 invention patents, with over ten new drug projects currently under research. From 2002 to 2005, it completed the development of the TCM new drug "Xiaoyu Jiangzhi Capsules" under the "863 Program" and successfully obtained the New Drug Certificate; this project was also included in the National Development and Reform Commission's High-Tech Industrialization Project (Biomedicine) in 2007; in 2008, "Kuntai Capsules" won the First Prize of the China Association of Traditional Chinese Medicine Science and Technology Award; in 2009, it received a "Major New Drug Discovery" national sci-tech major project. Guiyang Xintian Pharmaceutical Co., Ltd. was founded in August 1995 and listed on the SME Board of the Shenzhen Stock Exchange on May 19, 2017, with stock abbreviation: Xintian Pharmaceutical, stock code: 002873. The company belongs to the Chinese patent medicine manufacturing industry in the pharmaceutical manufacturing sector, possessing GMP-certified production lines for eight dosage forms, including hard capsules, mixtures, granules, gels, tablets, syrups, tinctures, and sprays, as well as two TCM decoction piece production lines (Line A and Line B). It is primarily engaged in the research, development, production, and sales of Chinese patent medicines for urological diseases, gynecological diseases, and other diseases with complex etiologies, providing safe and effective products to patients. 1. Product Advantages: The company currently produces 11 products, and its leading products, Ningmitai Capsules, Kuntai Capsules, Kushen Gel, and Xiakucao Oral Liquid, are all exclusive domestic varieties. 2. Product Reserve Advantages: The company arranges R&D activities according to the requirement of "produce one generation, reserve one generation, and develop one generation." After more than a decade of development, the company's R&D efforts have accumulated sufficient capabilities to meet the demand for launching new products. Currently, the company has 11 products in production, of which 4 are the main existing products, 7 are planned to transition from small-batch to batch production in the future, and 2 have obtained registration approvals and are planned for production. The rich product reserve provides a guarantee for the company's rapid development over a longer period in the future. 3. R&D Advantages: The company has always attached importance to R&D, considering R&D capability as one of the most important factors for sustainable development and an integral part of its core competitiveness. Currently, the company holds 40 invention patents, 1 utility model patent, and 5 design patents. It has obtained 11 New Drug Certificates and 54 drug approval numbers. 4. Academic Promotion and Professional Marketing Team Advantages: In recent years, based on an accurate grasp of national healthcare reform direction and the development trend of Chinese patent medicine sales, the company adheres to "service-oriented sales, specialized promotion, and high-quality products," vigorously strengthening its marketing management system to adapt to the new situation where its leading products enter the National Medical Insurance Catalog and the National Essential Drug List. In addition, it implements a manager responsibility system in regional markets and adopts specialized division of labor among marketing personnel to further strengthen academic promotion and deepen service marketing. After years of unremitting team building, the company has developed a professional and stable professional marketing team. The construction of the marketing team is based on local recruitment, continuously improving reasonable and effective marketing management systems, strengthening training and management of sales personnel, improving the business skills of existing sales personnel, and shaping the marketing team into a competitive, learning-oriented, innovative, and professional team that has a deep understanding and recognition of the corporate culture, full confidence in the company's long-term development, and a high degree of loyalty. Through professional academic promotion, the company has increased the trust of clinical medical staff in the company and its products, effectively maintaining the relationship among the company, pharmaceutical commercial companies, and hospitals. Coupled with the professional and stable marketing team accumulated over years, the company's marketing advantages are relatively prominent. As of December 2018, the company has a sales team of more than 800 people, established over 100 regional offices across 30 provinces, autonomous regions, and municipalities directly under the central government, covering over 10,000 county (district) level and above hospitals with prescription drugs, including over 1,600 tertiary hospitals, and has established long-term stable business relationships with over 1,000 medical commercial units in China; OTC products cover over 600 pharmaceutical chain companies and over 57,000 stores, with long-term stable business relationships established with more than 370 pharmaceutical chain company headquarters nationwide.